Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies Review


Authors: Weirauch, U.; Kreuz, M.; Birkenbihl, C.; Alb, M.; Quaranta, M.; Calzone, L.; Orozco-Ruiz, S.; Binder, S.; Fischer, L.; Clavreul, S.; Maguri, M.; Ferle, M.; Rade, M.; Azarias, G.; Hydren, J. R.; Jamarik, J.; Schwarz, D.; Sebestyen, Z.; Kuball, J.; Popp, G.; Antoine, C.; Knockaert, M.; Schoeder, C. T.; Fandrei, D.; Sanges, C.; Radvilas, V.; Gagelmann, N.; Rückert, M.; Penack, O.; Fricke, S.; Schmidt, A.; Ward, C.; Steinbeisser, C.; Van Gyseghem, J. M.; Niarakis, A.; Garderet, L.; Hudecek, M.; Neumuth, T.; Platzbecker, U.; Köhl, U.; Demlova, R.; Kremer, A.; Franke, S.; Fröhlich, H.; Merz, M.; Reiche, K.; On behalf of the CERTAINTY Consortium
Review Title: Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies
Abstract: In (immune)oncology, virtual twins (VTs) offer patient-individual decision support. Nevertheless, current VTs do not incorporate the unique properties of engineered adoptive cellular immunotherapies (eACIs). Here, we outline the minimal design specifications for VTs for engineered ACIs (eACI-VTs) to model the complex interplay between cell product and patient physiology. We motivate utilizing VTs in eACIs to provide decision support and reflect on how eACI-VTs can support the widespread use of eACIs.
Keywords: therapy; cells; car; cancer
Journal Title: Npj Digital Medicine
Volume: 8
ISSN: 2398-6352
Publisher: Nature Portfolio  
Date Published: 2025-08-01
Start Page: 493
Language: English
ACCESSION: WOS:001542625700002
DOI: 10.1038/s41746-025-01809-6
PROVIDER: wos
PMCID: PMC12316993
PUBMED: 40750653
Notes: Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Maximilian Merz
    5 Merz